ANXV is under clinical development by Annexin Pharmaceuticals and currently in Phase II for Retinal Vein Occlusion.

Nerinetide is under clinical development by NoNO and currently in Phase III for Acute Ischemic Stroke. According to GlobalData, Phase III drugs for Acute Ischemic Stroke have a 13% phase transition ...

A multinational study led by the LHON Study Group has revealed sustained visual improvements and a favorable safety profile ...

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...

Clarity is not rated by Morgans. The retinal-diseases-focused biotech is awaiting two phase III trial results in CY25. The ...

Just when third installments begin to lag, the Sonic series has found a way to turbo-charge itself, doubling the Jim Carrey ...

Bayer announced positive topline results from the global phase III QUASAR study evaluating the efficacy and safety of aflibercept 8 mg in patients with macular edema following retinal vein occlusion ...

The German gene therapy developer will test VG801 in patients with Stargardt disease and other retinal dystrophies linked with ABCA4 mutations.

Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of ...

Regeneron and Bayer report positive Phase III results for Eylea HD in macular edema following retinal vein occlusion, showing ...

A retinal tear is a common age-related eye condition. It causes eye floaters and flashes of light and may lead to more severe vision problems. On its own, a torn retina will not damage your eyesight.